TrialThe New England journal of medicine2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J Kelly et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,048 papers cite itlatest 60 shown
this paperpooled ittrialcites it